Filing Flows › Health Care › Vycor Medical (VYCO)
Vycor Medical (VYCO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Vycor Medical (VYCO) Q2 2026 earnings results →
Q2 2026 Revenue down 16% year over year to $418K · 5¢ of every $1 of revenue lost · operating margin 1.6%
Vycor Medical made $418K in Q2 2026 (-16% Y/Y): Vycor Medical Inc $401K, NovaVision Inc $17K. Operating margin 1.6%, net loss $22K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $418K in Q2 2026, down 16% year over year and down 9% from the previous quarter. Vycor Medical Inc was the largest line at 96% of revenue. Vycor Medical Inc lost $81K year over year (down 17%), 103% of the total change.
Gross margin was 82.4%, down 1.3 points from Q2 2025. Operating profit was $7K, a 1.6% margin (down 8.7 points year over year). Operating expenses fell 7% while revenue fell 16%. The quarter ended with a net loss of $22K, after a profit of $20K the previous quarter. Net interest and other expense of $26K was the main reason.
Operating cash flow was −$5K. Non-cash charges added back $15K of depreciation and amortization. Working capital and other items added $3K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $418K | -16% | 1.6% | −$22K | −$5K |
| Q1 2026 | 10-Q | May 15, 2026 | $459K | +5% | 10.0% | $20K | $99K |
| Q4 2025 | 10-K | Mar 31, 2026 | $417K | -8% | -8.8% | −$63K | $39K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $514K | +32% | 6.2% | $5K | −$72K |
| Q2 2025 | 10-Q | Aug 8, 2025 | $496K | +22% | 10.3% | $24K | $47K |
| Q1 2025 | 10-Q | May 15, 2025 | $436K | +30% | -2.9% | −$39K | −$27K |
| Q4 2024 | 10-K | Apr 15, 2025 | $455K | +48% | 4.2% | −$7K | −$38K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Vycor Medical
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical’s FDA-cleared ViewSite™ Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over 350 hospitals in the US and in numerous countries internationally.
In its own words, from its 8-K, filed Aug 14, 2026.
Vycor Medical against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -16% against the peers' median +5%. Operating margin: 1.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VYCO Vycor Medical | Q2 2026 | $418K | -16% | 1.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Vycor Medical 10-Q on SEC EDGAR · CIK 1424768 · Surgical & Medical Instruments & Apparatus
More on VYCO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results